No reference-scaling for NTIDs [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2021-08-02 14:57 (329 d 14:31 ago) – Posting: # 22498
Views: 1,497

Hi Prasad,

» Little bit confusion raised as the Gliclazide is a NTI molecule, what would be the study design for gliclazide 80mg tablet BE study for Europe, WHO & HKG submission.

If you are referring to Hong Kong, guidances of China’s CDE are applicable.

Adding to what vixen wrote: Reference-scaling (ABEL: the EMA, most jurisdictions including the WHO or RSABE: U.S. FDA and China’s CDE) for NTIDs is not acceptable.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,178 posts in 4,646 threads, 1,571 registered users;
online 10 (0 registered, 10 guests [including 6 identified bots]).
Forum time: Tuesday 05:29 CEST (Europe/Vienna)

It is futile to do with more things
that which can be done with fewer.    William of Ockham

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5